{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:05:05Z","timestamp":1783037105600,"version":"3.54.6"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study aims to assess the clinical efficacy and safety of omadacycline for the treatment of acute bacterial infections in adult patients through meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, Embase, ClinicalTrials.gov, and Cochrane databases were searched up to May 2019. Only randomized controlled trials (RCTs) that evaluated omadacycline and other comparators for treating acute bacterial infections in adult patients were included. The primary outcome was the clinical response rate at the posttreatment evaluation, whereas the secondary outcomes were risk of an adverse event (AE) and mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Four RCTs were included. Overall, omadacycline had a clinical response rate noninferior to comparators in the treatment of acute bacterial infection in the modified intent-to-treat population (odds ratio [OR], 1.31; 95% confidence interval [CI], 1.04\u20131.65; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%) and in the clinically evaluable population (OR, 1.53; 95% CI, 1.11\u20132.11; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%). Furthermore, no significant differences were found between omadacycline and comparators for the risk of treatment-emergent AEs (OR, 1.13; 95% CI, 0.60\u20132.14; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a93%), treatment-related AEs (OR, 0.70; 95% CI, 0.46\u20131.04; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a56%), serious AEs (OR, 1.01; 95% CI, 0.64\u20131.58; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%), and discontinuation of study drug due to an AE (OR, 0.78; 95% CI, 0.47\u20131.29; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%). However, in the clinical trial, NCT02877927, in which omadacycline was used in only oral form, the reported incidence of nausea and vomiting were 30.2% (111\/368) and 16.9% (62\/368), respectively. Finally, the mortality rate was similar between omadacycline and comparator in the treatment of acute bacterial infection (OR, 1.32; 95% CI, 0.47\u20133.67; <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a0%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The clinical efficacy of omadacycline is not inferior to that of comparators in the treatment of acute bacterial infections in adult patients, and this antibiotic is also well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018426","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T17:37:51Z","timestamp":1576777071000},"page":"e18426","source":"Crossref","is-referenced-by-count":12,"title":["The efficacy and safety of omadacycline in treatment of acute bacterial infection"],"prefix":"10.1097","volume":"98","author":[{"given":"Shao-Huan","family":"Lan","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Peng","family":"Chang","sequence":"additional","affiliation":[{"name":"Yijia Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chin","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Management, Putian University, Putian"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ming","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","DOI":"10.3390\/ph12020063","article-title":"Omadacycline: a newly approved antibacterial from the class of tetracyclines","volume":"12","author":"Dur\u00e3es","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"R2-20230915","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02262-18","article-title":"Antimicrobial activity of omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)","volume":"63","author":"Carvalhaes","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20230915","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00018-17","article-title":"Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20230915","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20230915","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02411-16","article-title":"Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20230915","article-title":"In vitro activity of omadacycline against Chlamydia pneumoniae","volume":"63","author":"Kohlhoff","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20230915","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00047-18","article-title":"In vitro activities of omadacycline and comparators against anaerobic bacteria","volume":"62","author":"Stapert","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2017.10.010","article-title":"Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014)","volume":"90","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/cid\/ciz242","article-title":"Omadacycline: a novel tetracycline derivative with oral and intravenous formulations","volume":"69","author":"Watkins","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.01242-13","article-title":"In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline","volume":"58","author":"Macone","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diagmicrobio.2018.01.019","article-title":"Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1128\/AAC.00948-12","article-title":"A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.02.017","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme, 2017","volume":"19","author":"Huband","year":"2019","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:01:48Z","timestamp":1694818908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018426"}},"subtitle":["A systemic review and meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":16,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018426","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}